Rein Therapeutics’ (RNTX) “Hold” Rating Reaffirmed at Brookline Capital Management

Brookline Capital Management reaffirmed their hold rating on shares of Rein Therapeutics (NASDAQ:RNTX) in a report published on Wednesday morning,Benzinga reports.

Several other analysts have also recently issued reports on the company. Wall Street Zen cut Rein Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, December 14th. Citigroup downgraded Rein Therapeutics to a “hold” rating in a report on Wednesday. Loop Capital set a $6.00 price objective on Rein Therapeutics in a research note on Monday, November 3rd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Rein Therapeutics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $8.00.

Rein Therapeutics Stock Performance

Shares of RNTX stock opened at $1.21 on Wednesday. Rein Therapeutics has a fifty-two week low of $1.02 and a fifty-two week high of $3.50. The company has a 50 day moving average price of $1.32 and a 200 day moving average price of $1.31. The stock has a market capitalization of $31.81 million, a P/E ratio of -0.46 and a beta of 1.31.

Rein Therapeutics (NASDAQ:RNTX) last released its earnings results on Friday, November 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.03. On average, research analysts forecast that Rein Therapeutics will post -1.56 EPS for the current fiscal year.

Insider Activity at Rein Therapeutics

In other Rein Therapeutics news, major shareholder Voss Capital, Lp bought 178,392 shares of the business’s stock in a transaction dated Tuesday, October 28th. The shares were acquired at an average price of $1.39 per share, with a total value of $247,964.88. Following the transaction, the insider owned 500,000 shares of the company’s stock, valued at approximately $695,000. The trade was a 55.47% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last quarter, insiders bought 410,233 shares of company stock valued at $550,563. Corporate insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On Rein Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RNTX. Gleason Group Inc. acquired a new stake in Rein Therapeutics during the third quarter worth approximately $26,000. Blair William & Co. IL purchased a new position in shares of Rein Therapeutics in the 2nd quarter valued at $33,000. Meridian Wealth Advisors LLC purchased a new position in shares of Rein Therapeutics in the 2nd quarter valued at $40,000. Exencial Wealth Advisors LLC acquired a new stake in Rein Therapeutics during the 2nd quarter worth $43,000. Finally, Susquehanna International Group LLP purchased a new stake in Rein Therapeutics in the third quarter valued at $35,000. 90.89% of the stock is owned by institutional investors and hedge funds.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.